Inclusion Criteria:

          -  Metastatic breast cancer HER2-/RH+

          -  Progression after hormonotherapy

          -  Treated by taxanes, anthracyclines, capecitabine and eribulin

          -  Treated by everolimus

          -  ECOG ≤ 2

          -  Hematological Function: neutrophiles ≥ 1,5 x 109 / L, hemoglobin ≥ 9 g / dL, plaques ≥
             100 x 109 / L

          -  Hepatic function: albumin ≥ 2,5 g / dl, bilirubin serum ≤ 2 x N (superior border of
             the standard) (unless disease of Gilbert), transaminases ≥ 3 x N

          -  Renal Function: serum creatinine ≤ 1,5 mg / dL or clearance of the creatinine ≥ 40 mL
             / min

          -  Estimated Life expectancy ≥ 3 months

        Exclusion Criteria:

          -  Hypersensitivity known about one of the constituents of the estramustine phosphates

          -  Preliminary Treatment by estramustine phosphates

          -  Brain Metastases

          -  Patients not being under effective contraception

          -  Minor, pregnant or lactating Patients

          -  Patients not previously treated by everolimus

          -  Transaminases > 3xN

          -  Other concomitant anticancer treatment less than 1 month before the inclusion

          -  Digestive function: malabsorption

          -  History of other cancer in the previous 5 years (other than squamous-cell epithelioma
             or totally resected in situ carcinoma)

          -  Active Thrombo-phlebitis

          -  Risk thromboembolic known,

          -  Unchecked cardiovascular Pathology

          -  Grave hepatic Affection